Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl transcripts
✍ Scribed by Toshinori Kondo; Taizo Tasaka; Fuminori Sano; Kimiko Matsuda; Yasutaka Kubo; Yoshiko Matsuhashi; Hidekazu Nakanishi; Yoshito Sadahira; Hideho Wada; Takashi Sugihara; Kaoru Tohyama
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 159 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
✦ Synopsis
We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revealed only one-log reduction with IM monotherapy, suggesting a resistance against IM, and this patient required additional chemotherapy. Despite the resistance against IM at induction therapy, the patient has been in complete molecular response for more than 6 months with IM maintenance monotherapy. Our experience suggests that IM might have a positive role in consolidation and/or maintenance therapy in remission Ph + AML patients.